Anti-PD-1 Antibody Treatment With Cemiplimab and Radiotherapy in Early-stage Classical Hodgkin Lymphoma

NCT04373083 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Business Decision

Conditions

Hodgkin Lymphoma

Interventions

DRUG: Cemiplimab
RADIATION: Involved-site radiotherapy (IS-RT)

Sponsor

Regeneron Pharmaceuticals

Collaborators

[object Object]